Publications

Nadia Procopio
Nadia Procopio
Global Executive Marketing Operation Stream Leader and FemTech Ambassador @PQE Group
Share this article

Medical Cannabis: Legislative Challenges, Medical Control, FemTech and Social Sensitivity  

Medical cannabis is an increasingly relevant topic in our society, where legislative restrictions, medical control, and growing social sensitivity intersect. Its adoption as a therapeutic treatment, though recognized for its benefits in conditions such as chronic pain, epilepsy, and multiple sclerosis, remains a subject of debate. 

EUROPE 

In Europe, the use of medical cannabis varies significantly between countries. According to the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Germany and Italy are among the main users, with approximately 128,000 patients in Germany in 2020 and a growing number in Italy. Conversely, countries like France maintain stricter restrictions, with only limited pilot programs. Germany, for instance, is one of the most advanced countries in terms of access to medical cannabis. Since 2017, doctors can prescribe cannabis for therapeutic purposes, and in 2020, around 128,000 German patients were using it. In Italy, the situation is similar, with an increasing number of patients accessing medical cannabis to treat various conditions, including chronic pain and spasticity from multiple sclerosis. However, in other European countries like France, access to medical cannabis is much more limited, often confined to narrow pilot programs. 

UNITED STATES 

In the United States, the situation is different. Twenty-one states, along with Washington D.C., have legalized the use of medical cannabis. According to a report by the National Conference of State Legislatures (NCSL), over 5 million patients were registered for medical cannabis use in 2022. However, legalization varies widely from state to state, creating a patchwork of regulations. Twenty-one states, along with Washington D.C., have legalized the use of cannabis for medical purposes. In 2022, over 5 million patients were registered for medical cannabis use, according to the National Conference of State Legislatures (NCSL). However, regulations vary widely from state to state, creating a mosaic of laws and rules that can confuse patients and healthcare professionals. 

CLINICAL STUDIES 

Clinical studies are crucial for understanding the efficacy of medical cannabis. A review published in JAMA in 2021 analyzed 79 randomized clinical trials involving over 6,400 participants. The results showed that medical cannabis can significantly reduce chronic pain and spasticity symptoms in multiple sclerosis. However, the authors emphasize the need for further research to confirm these findings and establish optimal dosages. A systematic review published in JAMA in 2021 analyzed 79 randomized clinical trials involving over 6,400 participants. The results indicated that medical cannabis can significantly reduce chronic pain and spasticity symptoms in multiple sclerosis. However, the authors of the review stressed the need for further research to confirm these results and establish optimal dosages and treatment guidelines. 

SOCIAL SENSITIVITY 

In this context, social sensitivity towards medical cannabis is growing. Many patients and doctors advocate for broader and more regulated access, while others raise concerns about potential abuse and side effects. It is crucial to balance regulation with patient support, ensuring that medical cannabis is used safely and effectively. Increasingly, patients and doctors recognize the therapeutic potential of cannabis and advocate for broader, regulated access. However, there are also legitimate concerns about potential abuse and side effects. It is essential that public policies strike a balance between the need to regulate medical cannabis use and the support for patients who can benefit from this therapy. 

MEDICAL CANNABIS AND FEMTECH 

A significant and emerging area where medical cannabis is gaining traction is in the FemTech (female technology) sector. FemTech encompasses products, services, and software that cater to women’s health, including areas such as menstrual health, reproductive health, and menopause. Medical cannabis is being explored for its potential benefits in alleviating conditions such as menstrual pain, endometriosis, and symptoms associated with menopause. As more research validates these benefits, medical cannabis could become a vital component of FemTech solutions, providing women with more options for managing their health. This intersection of medical cannabis and FemTech highlights the need for inclusive and comprehensive research, as well as legislation that supports innovative treatments for women’s health issues. 

MEDICAL CANNABIS AND ITS FUTURE 

The future of medical cannabis will depend on society’s ability to balance these different aspects. An open and informed dialogue, based on solid scientific evidence, is essential to develop policies that ensure both patient safety and access to treatments. The regulation of medical cannabis must be flexible and adaptable, taking into account new scientific discoveries and patient needs. Additionally, it is important to educate both the public and healthcare professionals about the benefits and risks of medical cannabis. Awareness and training campaigns can help overcome prejudices and misinformation, promoting a conscious and responsible use of medical cannabis. 

In conclusion, medical cannabis represents both a challenge and an opportunity for our society. Legislative restrictions and medical control must be balanced with growing social sensitivity and the need to support patients. Only through a balanced and informed approach can the therapeutic benefits of medical cannabis be fully utilized, ensuring patient safety and well-being. 

Sources: 

European Monitoring Centre for Drugs and Drug Addiction (EMCDDA): 

Official website of the EMCDDA: emcdda.europa.eu 

National Conference of State Legislatures (NCSL): 

Report on the legalization of medical cannabis in the United States: ncsl.org 

JAMA (Journal of the American Medical Association): 

Systematic review of clinical studies on medical cannabis: 

Hill, K.P. (2015). Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems: A Clinical Review. JAMA, 313(24), 2474-2483. doi:10.1001/jama.2015.6199 

Articles and research reports: 

Article from 2021 published in JAMA: 

Whiting, P.F., Wolff, R.F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A.V., Keurentjes, J.C., Lang, S., Misso, K., Ryder, S., Schmidlkofer, S., Westwood, M., Kleijnen, J. (2015). Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA, 313(24), 2456-2473. doi:10.1001/jama.2015.6358 

Statistics and patient reports: 

Data on patients registered for medical cannabis use in Germany and the United States: 

BfArM (Federal Institute for Drugs and Medical Devices): bfarm.de 

Department of Health and Human Services USA: hhs.gov 

Related Publications

Discover more about this topic and get the latest updates about the cannabis industry.